441 related articles for article (PubMed ID: 28646122)
21. H
Zhou Y; Zhu X; Wang X; Peng Y; Du J; Yin H; Yang H; Ni X; Zhang W
Exp Cell Res; 2020 Feb; 387(1):111779. PubMed ID: 31846625
[TBL] [Abstract][Full Text] [Related]
22. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro.
Meng XM; Huang XR; Xiao J; Chen HY; Zhong X; Chung AC; Lan HY
J Pathol; 2012 Jun; 227(2):175-88. PubMed ID: 22190171
[TBL] [Abstract][Full Text] [Related]
23. RON Receptor Tyrosine Kinase Regulates Epithelial Mesenchymal Transition and the Expression of Pro-Fibrotic Markers via Src/Smad Signaling in HK-2 and NRK49F Cells.
Park JS; Choi HI; Kim DH; Kim CS; Bae EH; Ma SK; Kim SW
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31690042
[TBL] [Abstract][Full Text] [Related]
24. FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts.
Tian T; Zhang J; Zhu X; Wen S; Shi D; Zhou H
Clin Exp Immunol; 2017 Oct; 190(1):68-78. PubMed ID: 28658504
[TBL] [Abstract][Full Text] [Related]
25. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy.
Yang J; Liu Y
Am J Physiol Renal Physiol; 2003 Feb; 284(2):F349-57. PubMed ID: 12529273
[TBL] [Abstract][Full Text] [Related]
26. Telbivudine attenuates UUO-induced renal fibrosis via TGF-β/Smad and NF-κB signaling.
Chen J; Li D
Int Immunopharmacol; 2018 Feb; 55():1-8. PubMed ID: 29207359
[TBL] [Abstract][Full Text] [Related]
27. Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice.
Singh SP; Tao S; Fields TA; Webb S; Harris RC; Rao R
Dis Model Mech; 2015 Aug; 8(8):931-40. PubMed ID: 26092126
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis.
Jiao B; An C; Tran M; Du H; Wang P; Zhou D; Wang Y
Front Immunol; 2021; 12():735014. PubMed ID: 34512669
[TBL] [Abstract][Full Text] [Related]
29. Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis.
Xavier S; Sahu RK; Landes SG; Yu J; Taylor RP; Ayyadevara S; Megyesi J; Stallcup WB; Duffield JS; Reis ES; Lambris JD; Portilla D
Am J Physiol Renal Physiol; 2017 Mar; 312(3):F516-F532. PubMed ID: 28052876
[TBL] [Abstract][Full Text] [Related]
30. Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT.
Zhu X; Shi D; Cao K; Ru D; Ren J; Rao Z; Chen Y; You Q; Dai C; Liu L; Zhou H
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3824-3836. PubMed ID: 30251698
[TBL] [Abstract][Full Text] [Related]
31. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract][Full Text] [Related]
32. IRF-4 deficiency reduces inflammation and kidney fibrosis after folic acid-induced acute kidney injury.
Chen M; Wen X; Gao Y; Liu B; Zhong C; Nie J; Liang H
Int Immunopharmacol; 2021 Nov; 100():108142. PubMed ID: 34555644
[TBL] [Abstract][Full Text] [Related]
33. Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis.
Ponnusamy M; Zhuang MA; Zhou X; Tolbert E; Bayliss G; Zhao TC; Zhuang S
J Pharmacol Exp Ther; 2015 Aug; 354(2):142-51. PubMed ID: 26022003
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model.
Yang M; Chen G; Zhang X; Guo Y; Yu Y; Tian L; Chang S; Chen ZK
Pharmacol Res; 2019 Apr; 142():192-204. PubMed ID: 30807866
[TBL] [Abstract][Full Text] [Related]
35. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.
Moon JA; Kim HT; Cho IS; Sheen YY; Kim DK
Kidney Int; 2006 Oct; 70(7):1234-43. PubMed ID: 16929250
[TBL] [Abstract][Full Text] [Related]
36. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib mitigates renal fibrosis in a rat model of UUO via inhibition of Src/STAT-3/NF-κB signaling.
Hassan NME; Shehatou GSG; Kenawy HI; Said E
Environ Toxicol Pharmacol; 2021 May; 84():103625. PubMed ID: 33617955
[TBL] [Abstract][Full Text] [Related]
38. Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy.
Ponnusamy M; Zhou X; Yan Y; Tang J; Tolbert E; Zhao TC; Gong R; Zhuang S
J Pharmacol Exp Ther; 2014 Aug; 350(2):243-56. PubMed ID: 24833701
[TBL] [Abstract][Full Text] [Related]
39. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
40. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Liu F; Bayliss G; Zhuang S
Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
